ISN Frontiers Webinar: New Insights into Clinical Management of C3G
Recorded On: 12/10/2021
Supported by an educational grant from Alexion Pharmaceuticals Inc. AstraZeneca Rare Disease
The drugs that are currently used, such as corticosteroids and immunosuppressants, are frequently ineffective in C3G . Eculizumab, an anti-C5 monoclonal antibody, has been used occasionally however, only a few patients have achieved remission. This heterogeneous response could be related to the extent of terminal complement activation. The webinar will focus on drugs that target the complement system at different levels and are under investigation for C3G . Clinical trials to test new therapeutics will be challenging and heavily influenced by the heterogeneity of this disease. This creates the need to characterize each patient to match the specific complement abnormality with the type of intervention.